Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study. (avaa uuden ikkunan)

Abdelrazik N, Fouda M

Lähde‎: Hematology 2007;12(6):533-41.

Arkistoitu‎: PubMed 17852440

DOI‎: 10.1080/10245330701521572

https://www.ncbi.nlm.nih.gov/pubmed/17852440 (avaa uuden ikkunan)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (avaa uuden ikkunan)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Lähde‎: Cancer 2012;118(3):848-55.

Arkistoitu‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (avaa uuden ikkunan)

Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment. (avaa uuden ikkunan)

Corapcioglu F, Aksu G, Basar EZ, Demirel A, Oncel S, Mutlu A

Lähde‎: Pediatr Hematol Oncol 2008;25(6):509-21.

Arkistoitu‎: PubMed 18728970

DOI‎: 10.1080/08880010802235132

https://www.ncbi.nlm.nih.gov/pubmed/18728970 (avaa uuden ikkunan)

Recombinant human erythropoietin beta: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients. (avaa uuden ikkunan)

Durmaz O, Demirkaya M, Sevinir B

Lähde‎: Pediatr Hematol Oncol 2011;28(6):461-8.

Arkistoitu‎: PubMed 21707225

DOI‎: 10.3109/08880018.2011.570857

https://www.ncbi.nlm.nih.gov/pubmed/21707225 (avaa uuden ikkunan)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (avaa uuden ikkunan)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Lähde‎: J Clin Oncol 2010;28(13):2239-45.

Arkistoitu‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (avaa uuden ikkunan)

Treatment patterns and outcomes in management of solid cancer patients suffering from anemia in Penang hospital. (avaa uuden ikkunan)

Hassan BA, Yusoff ZB

Lähde‎: Asian Pac J Cancer Prev 2011;12(6):1573-6.

Arkistoitu‎: PubMed 22126501

https://www.ncbi.nlm.nih.gov/pubmed/22126501 (avaa uuden ikkunan)

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. (avaa uuden ikkunan)

Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K; ARANESP 20030232 Study Group

Lähde‎: Curr Med Res Opin 2009;25(9):2109-20.

Arkistoitu‎: PubMed 19601709

DOI‎: 10.1185/03007990903084164

https://www.ncbi.nlm.nih.gov/pubmed/19601709 (avaa uuden ikkunan)

Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. (avaa uuden ikkunan)

Hinds PS, Hockenberry M, Feusner J, Hord JD, Rackoff W, Rozzouk BI

Lähde‎: J Support Oncol 2005;3(6 Suppl 4):10-1.

Arkistoitu‎: PubMed 16355549

https://www.ncbi.nlm.nih.gov/pubmed/16355549 (avaa uuden ikkunan)

The efficacy of recombinant human erythropoietin in treatment chemotherapy induced anemia in children diagnosed with a solid cancer. (avaa uuden ikkunan)

Hiradfar A, Banihosseinian M

Lähde‎: Iran J Ped Hematol Oncol 2014;4(4):151-9.

Arkistoitu‎: PubMed 25598955

https://www.ncbi.nlm.nih.gov/pubmed/25598955 (avaa uuden ikkunan)

2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. (avaa uuden ikkunan)

Marec-Berard P, Chastagner P, Kassab-Chahmi D, Casadevall N, Marchal C, Misset JL, Ray-Coquard I.

Lähde‎: Pediatr Blood Cancer 2009;53(1):7-12.

Arkistoitu‎: PubMed 19229970

DOI‎: 10.1002/pbc.21953

https://www.ncbi.nlm.nih.gov/pubmed/19229970 (avaa uuden ikkunan)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (avaa uuden ikkunan)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Lähde‎: Cancer 2013;119(1):107-14.

Arkistoitu‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (avaa uuden ikkunan)

Erythropoietic growth factors for children with cancer: a systematic review of the literature. (avaa uuden ikkunan)

Mystakidou K, Potamianou A, Tsilika E

Lähde‎: Curr Med Res Opin 2007;23(11):2841-7.

Arkistoitu‎: PubMed 17910805

DOI‎: 10.1185/030079907x242601

https://www.ncbi.nlm.nih.gov/pubmed/17910805 (avaa uuden ikkunan)

Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. (avaa uuden ikkunan)

Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, Rackoff WR

Lähde‎: J Clin Oncol 2006;24(22):3583-9.

Arkistoitu‎: PubMed 16877725

DOI‎: 10.1200/JCO.2005.03.4371

https://www.ncbi.nlm.nih.gov/pubmed/16877725 (avaa uuden ikkunan)

The role of recombinant erythropoietin in childhood cancer. (avaa uuden ikkunan)

Shankar AG

Lähde‎: Oncologist 2008;13(2):157-66.

Arkistoitu‎: PubMed 18305061

DOI‎: 10.1634/theoncologist.2007-0126

https://www.ncbi.nlm.nih.gov/pubmed/18305061 (avaa uuden ikkunan)

Efficacy and safety of iorEPOCIM for chemotherapy- or radiotherapy-induced anemia in pediatric cancer patients. (avaa uuden ikkunan)

Vargas A, Mendoza I, Uranga R, González A, Martínez L, Caballero I, Piedra P, Saurez G, Verdecia M, Cabanas R

Lähde‎: MEDICC Rev 2010;12(3):27-31.

Arkistoitu‎: PubMed 20697335

DOI‎: 10.37757/MR2010.V12.N3.7

https://www.ncbi.nlm.nih.gov/pubmed/20697335 (avaa uuden ikkunan)

A single institutional experience: is epoetin alpha effective in anemic children with cancer? (avaa uuden ikkunan)

Yilmaz D, Cetingül N, Kantar M, Oniz H, Kansoy S, Kavakli K

Lähde‎: Pediatr Hematol Oncol 2004;21(1):1-8.

Arkistoitu‎: PubMed 14660300

https://www.ncbi.nlm.nih.gov/pubmed/14660300 (avaa uuden ikkunan)

Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy. (avaa uuden ikkunan)

Zachariah M, Elshinawy M, Alrawas A, Bashir W, Elbeshlawi I, Tony S, Wali Y

Lähde‎: Pediatr Hematol Oncol 2014;31(5):442-7.

Arkistoitu‎: PubMed 24088186

DOI‎: 10.3109/08880018.2013.824527

https://www.ncbi.nlm.nih.gov/pubmed/24088186 (avaa uuden ikkunan)

Early epoetin alfa treatment in children with solid tumors. (avaa uuden ikkunan)

Zoubek A, Kronberger M

Lähde‎: Med Pediatr Oncol 2002;39(4):459-62.

Arkistoitu‎: PubMed 12203664

DOI‎: 10.1002/mpo.10186

https://www.ncbi.nlm.nih.gov/pubmed/12203664 (avaa uuden ikkunan)

Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. (avaa uuden ikkunan)

Crary SE, Hall K, Buchanan GR.

Lähde‎: Pediatr Blood Cancer 2011;56(4):615-9.

Arkistoitu‎: PubMed 21298748

DOI‎: 10.1002/pbc.22930

https://www.ncbi.nlm.nih.gov/pubmed/21298748 (avaa uuden ikkunan)

Intravenous iron sucrose for children with iron deficiency anemia. (avaa uuden ikkunan)

Kaneva K, Chow E, Rosenfield CG, Kelly MJ

Lähde‎: J Pediatr Hematol Oncol 2017;39(5):e259-62.

Arkistoitu‎: PubMed 28562517

DOI‎: 10.1097/MPH.0000000000000879

https://www.ncbi.nlm.nih.gov/pubmed/28562517 (avaa uuden ikkunan)

Advances in Pediatric Intravenous Iron Therapy. (avaa uuden ikkunan)

Mantadakis E.

Lähde‎: Pediatr Blood Cancer 2016;63(1):11-6.

Arkistoitu‎: PubMed 26376214

DOI‎: 10.1002/pbc.25752

https://www.ncbi.nlm.nih.gov/pubmed/26376214 (avaa uuden ikkunan)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (avaa uuden ikkunan)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Lähde‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Arkistoitu‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (avaa uuden ikkunan)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (avaa uuden ikkunan)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Lähde‎: J Clin Oncol 2008;26(10):1619-25.

Arkistoitu‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (avaa uuden ikkunan)

Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron. (avaa uuden ikkunan)

Plummer ES, Crary SE, McCavit TL, Buchanan GR

Lähde‎: Pediatr Blood Cancer 2013;60(11):1747-52.

Arkistoitu‎: PubMed 23832487

DOI‎: 10.1002/pbc.24676

https://www.ncbi.nlm.nih.gov/pubmed/23832487 (avaa uuden ikkunan)